MassDevice

Data supports Boston Scientific Watchman FLX in stroke reduction

Boston Scientific (NYSE:BSX) announced new findings from the CHAMPION-AF trial supporting its Watchman FLX system.
KTBS 3

CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and ...

Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrilla ...
Medical Device and Diagnostic Industry (MD+DI)

Boston Scientific Eyes Market Expansion with Watchman FLX After CHAMPION-AF Success

CHAMPION-AF shows Boston Scientific's Watchman FLX as a safe, effective first-line option for stroke risk reduction in ...
TCTMD

Registry Shows Watchman FLX Beating First-Gen Device for Early LAAO Outcomes

SAN FRANCISCO, CA—The redesigned Watchman FLX device (Boston Scientific) provides safer left atrial appendage occlusion (LAAO) in patients with atrial fibrillation compared with the first-generation ...